Teva Pharmaceutical Industries Ltd. (TEVA)

23.90
0.14 0.59
NYSE : Health Technology
Prev Close 23.76
Open 23.65
Day Low/High 23.54 / 24.27
52 Wk Low/High 10.85 / 33.82
Volume 9.02M
Avg Volume 11.41M
Exchange NYSE
Shares Outstanding 1.02B
Market Cap 24.03B
EPS -16.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

FDA Moves to Make Life Easier for Generic Drug Companies

FDA Moves to Make Life Easier for Generic Drug Companies

Following up on a pledge to accelerate generic drugs into the marketplace to stoke price competition, the agency signals pending reform of the Risk Evaluation and Mitigation Strategy.

Sirius XM Radio, Teva Pharmaceuticals: 'Mad Money' Lightning Round

Sirius XM Radio, Teva Pharmaceuticals: 'Mad Money' Lightning Round

Jim Cramer weighs in on Sirius XM Radio, Teva Pharmaceuticals, iQIYI, Blue Apron, Shopify, Incyte, E*Trade Financial and more.

Big Turnaround Stories: Cramer's 'Mad Money' Recap (Wednesday 5/23/18)

Big Turnaround Stories: Cramer's 'Mad Money' Recap (Wednesday 5/23/18)

Jim Cramer tells investors to keep their eyes open for companies making changes -- that's what's being rewarded.

Teva Confirms September PDUFA Date For Fremanezumab

Teva Confirms September PDUFA Date For Fremanezumab

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed that the U.

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Here's what you need to know now for Friday, May 18.

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Aimovig is the first treatment approved by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor.

Dow Closes Higher as Wall Street Weighs Rising Rates

Dow Closes Higher as Wall Street Weighs Rising Rates

The Dow, S&P 500 and Nasdaq all rose on Wednesday.

Teva Shares Jump After Warren Buffett Doubles Stake in Drugmaker

Teva Shares Jump After Warren Buffett Doubles Stake in Drugmaker

Berkshire Hathaway hiked its stake in the drugmaker, which is undergoing a restructuring, to 40.5 million shares as of the end of March.

CORRECTING And REPLACING Teva Announces Publication Of Phase III Trial Data Of Fremanezumab For The Preventive Treatment Of Episodic Migraine In The Journal Of The American Medical Association

CORRECTING And REPLACING Teva Announces Publication Of Phase III Trial Data Of Fremanezumab For The Preventive Treatment Of Episodic Migraine In The Journal Of The American Medical Association

First bulleted paragraph, second sentence of release dated May 15, 2018 should contain the numbers 4.

Teva Shows Progress on Restructuring But Investors Want More

Teva Shows Progress on Restructuring But Investors Want More

The Israel-based drugmaker reported first-quarter numbers that surpassed analysts' expectations but Wall Street wants to see more.

Dow Rises Slightly but S&P 500 and Nasdaq Finish Lower After Volatile Session

Dow Rises Slightly but S&P 500 and Nasdaq Finish Lower After Volatile Session

Shares of Tesla Inc., which reported earnings on Wednesday, fell by 5.5%

Teva Shares Spike After Q1 Earnings Beat, Full Year Forecast Boost

Teva Shares Spike After Q1 Earnings Beat, Full Year Forecast Boost

Teva shares edged into positive territory for the year Thursday after a stronger-than-expected start to the year allowed CEO Kåre Schultz to boost the generic drugmaker's 2018 earnings forecast.

Teva Reports First Quarter 2018 Financial Results

Teva Reports First Quarter 2018 Financial Results

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended March 31, 2018.

Teva To Present AUSTEDO® (deutetrabenazine) Tablets Data At The American Psychiatric Association 2018 Annual Meeting

Teva To Present AUSTEDO® (deutetrabenazine) Tablets Data At The American Psychiatric Association 2018 Annual Meeting

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced new scientific abstracts for AUSTEDO ® (deutetrabenazine) tablets will be presented at the American Psychiatric Association (APA) 2018 Annual Meeting in New York from May 5-9.

Teva Presents New Long-Term Data Demonstrating Efficacy And Safety Of COPAXONE® (glatiramer Acetate Injection) 40 Mg/mL

Teva Presents New Long-Term Data Demonstrating Efficacy And Safety Of COPAXONE® (glatiramer Acetate Injection) 40 Mg/mL

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced up to 7-year efficacy, safety and tolerability results from the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study of COPAXONE ® (glatiramer...

McDonald's, Nucor, Ball Corp.: 'Mad Money' Lightning Round

McDonald's, Nucor, Ball Corp.: 'Mad Money' Lightning Round

Jim Cramer shines a spotlight on McDonald's, Nucor, Ball Corp. United States Steel, Teva Pharmaceuticals, Chicago Mercantile Exchange and more.

Fools Rush In: Cramer's 'Mad Money' Recap (Wednesday 4/25/18)

Fools Rush In: Cramer's 'Mad Money' Recap (Wednesday 4/25/18)

Jim Cramer says he's still optimistic, and he doesn't want investors to give up. But he has 12 reasons to also remain cautious -- especially about Fridays.

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

The tough news keeps coming at the generic drug company, which announced last week it was considering putting itself up for sale. Now the Justice Department wants a chat.

Teva To Report First Quarter 2018 Financial Results On May 3, 2018

Teva To Report First Quarter 2018 Financial Results On May 3, 2018

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its first quarter 2018 financial results on Thursday, May 3, 2018 at 7:00 a.

Teva And The Procter & Gamble Company Have Agreed To Terminate The PGT Healthcare Partnership

Teva And The Procter & Gamble Company Have Agreed To Terminate The PGT Healthcare Partnership

Teva Pharmaceutical Industries [NYSE and TASE: TEVA] has announced that Teva and the Procter & Gamble Company [NYSE: PG] have agreed to terminate the PGT Healthcare partnership that the two companies established in 2011 to market OTC (Over The...

P&G Buys Consumer Healthcare Unit From Germany's Merck in First Peltz-Era Deal

P&G Buys Consumer Healthcare Unit From Germany's Merck in First Peltz-Era Deal

Procter & Gamble will pay around $4.2 billion for the consumer healthcare unit of Merck KGaA in the first major deal for the group since activist investor Nelson Peltz joined the board last month.

Mylan's Stock Gets Bump After Investor Day

Mylan's Stock Gets Bump After Investor Day

Following Wednesday's event, Leerink analyst Ami Fadia said she is 'incrementally more positive' on the drugmaker's pipeline and diversified business model and moved her rating to outperform.

American Medical Association Rejects Idea of Time Limits on Opioid Scripts

American Medical Association Rejects Idea of Time Limits on Opioid Scripts

While more than half the states in the U.S. have passed time limits on opioid prescription as a way to battle the epidemic, the AMA says that should be left up to the doctor and patient.

Trump's China Tariffs Could Hurt Generic Drug Companies and Increase Prices

Trump's China Tariffs Could Hurt Generic Drug Companies and Increase Prices

As President Trump tees up a set of 25% tariffs on a wide range of products against China trade, generic drug makers as well as their patients likely will be affected.

Teva Analyst: Wall Street's Forecasts Look 'Overly Ambitious'

Teva Analyst: Wall Street's Forecasts Look 'Overly Ambitious'

RBC's Randall Stanicky says concerns have moved from being about global generic growth to Teva's branded drug business.

Teva Announces The Launch Of A Generic Version Of Lialda® In The United States

Teva Announces The Launch Of A Generic Version Of Lialda® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Lialda ®1 (mesalamine) delayed-release tablets, 1.

Teva Announces The Launch Of A Generic Version Of ALOXI® In The United States

Teva Announces The Launch Of A Generic Version Of ALOXI® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced the launch of a generic version of ALOXI ®1 (palonosetron HCI) injection, 0.

Novartis Signs Agreement With Canadian Cannabis Company Tilray Regarding Med Pot

Novartis Signs Agreement With Canadian Cannabis Company Tilray Regarding Med Pot

Novartis subsidiary Sandoz Canada will work with cannabis producer Tilray to produce non-smokable medical cannabis products in Canada, becoming the first Big Pharma company to get into medical pot.

TheStreet Quant Rating: D+ (Sell)